5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Community-acquired pneumonia (CAP)/community-acquired bacterial pneumonia (CABP) and complicated skin and soft tissue infection (cSSTI)/acute bacterial skin and skin structure infection (ABSSSI) represent major causes of morbidity and mortality in children. β-Lactams are the cornerstone of antibiotic treatment for many serious bacterial infections in children; however, most of these agents have no activity against methicillin-resistant Staphylococcus aureus (MRSA). Ceftaroline fosamil, a β-lactam with broad-spectrum in vitro activity against Gram-positive pathogens (including MRSA and multidrug-resistant Streptococcus pneumoniae) and common Gram-negative organisms, is approved in the European Union and the United States for children with CAP/CABP or cSSTI/ABSSSI. Ceftaroline fosamil has completed a pediatric investigation plan including safety, efficacy, and pharmacokinetic evaluations in patients with ages ranging from birth to 17 years. It has demonstrated similar clinical and microbiological efficacy to best available existing treatments in phase III–IV trials in patients aged ≥ 2 months to < 18 years with CABP or ABSSSI, with a safety profile consistent with the cephalosporin class. It is also approved in the European Union for neonates with CAP or cSSTI, and in the US for neonates with ABSSSI. Ceftaroline fosamil dosing for children (including renal function adjustments) is supported by pharmacokinetic/pharmacodynamic modeling and simulations in appropriate age groups, and includes the option of 5- to 60-min intravenous infusions for standard doses, and a high dose for cSSTI patients with MRSA isolates, with a ceftaroline minimum inhibitory concentration of 2–4 mg/L. Considered together, these data suggest ceftaroline fosamil may be beneficial in the management of CAP/CABP and cSSTI/ABSSSI in children.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s40272-021-00468-w.

          Related collections

          Most cited references76

          • Record: found
          • Abstract: found
          • Article: not found

          Community-acquired pneumonia requiring hospitalization among U.S. children.

          Incidence estimates of hospitalizations for community-acquired pneumonia among children in the United States that are based on prospective data collection are limited. Updated estimates of pneumonia that has been confirmed radiographically and with the use of current laboratory diagnostic tests are needed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

            Community-acquired pneumonia is a leading infectious cause of hospitalization and death among U.S. adults. Incidence estimates of pneumonia confirmed radiographically and with the use of current laboratory diagnostic tests are needed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America

              Abstract Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.
                Bookmark

                Author and article information

                Contributors
                susannamariaroberta.esposito@unipr.it
                Journal
                Paediatr Drugs
                Paediatr Drugs
                Paediatric Drugs
                Springer International Publishing (Cham )
                1174-5878
                1179-2019
                31 August 2021
                31 August 2021
                2021
                : 23
                : 6
                : 549-563
                Affiliations
                [1 ]GRID grid.10383.39, ISNI 0000 0004 1758 0937, Pediatric Clinic, Pietro Barilla Children’s Hospital, , University of Parma, ; Building 15, Via Gramsci 14, 43126 Parma, Italy
                [2 ]GRID grid.431072.3, ISNI 0000 0004 0572 4227, AbbVie, ; Madison, NJ USA
                [3 ]GRID grid.410513.2, ISNI 0000 0000 8800 7493, Pfizer, ; Groton, CT USA
                [4 ]GRID grid.476471.7, ISNI 0000 0004 0593 9797, Pfizer, ; Paris, France
                Author information
                http://orcid.org/0000-0003-4103-2837
                Article
                468
                10.1007/s40272-021-00468-w
                8563558
                34462863
                5061a030-a7d6-4638-8da8-c36557a3525f
                © The Author(s) 2021, corrected publication 2021

                Open AccessThis article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 16 August 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100004319, Pfizer;
                Categories
                Review Article
                Custom metadata
                © Springer Nature Switzerland AG 2021

                Comments

                Comment on this article

                scite_

                Similar content211

                Cited by5

                Most referenced authors1,020